Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956382 · ClinicalTrials.gov registry record · Phase 1
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02956382 is a Phase 1 study that has completed, run by Georgetown University. The registered enrollment target is 24 participants.
The verdict
NCT02956382, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.
Interventions
- DRUG Venetoclax
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956382
The ClinicalTrials.gov registry entry for NCT02956382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Venetoclax is the first listed.
NCT02956382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02956382 about?
NCT02956382 is a clinical study titled "Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma". This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.
What is the current status of trial NCT02956382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-03-01. Estimated completion is 2024-03-07.
What interventions are being tested in trial NCT02956382?
The interventions under investigation include: Venetoclax (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02956382?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.